# Acute Tubular Necrosis: Intrinsic and Extrinsic Causes, Diagnosis, and Management

## Overview

Acute tubular necrosis (ATN) is the most common form of intrinsic acute kidney injury in hospitalized patients, accounting for 45–50% of AKI cases. It results from damage to tubular epithelial cells following either **ischemic insult** (most common, ~50% of ATN cases) or **nephrotoxic exposure** (~35%), with remaining cases representing combined mechanisms. Unlike functional prerenal azotemia or postrenal obstruction, ATN causes structural tubular epithelial damage with loss of cell-cell adhesion, apical-basolateral polarity disruption, and increased paracellular backleak. Recovery is possible but varies by severity, cause, and comorbidities.

------------------------------------------------------------------------

## 1. Pathophysiology of Acute Tubular Necrosis

### The S3 Segment: The Vulnerable Nexus

The **proximal straight tubule (S3 segment)** in the outer medulla bears the brunt of ischemic and toxic injury:

- **Anatomic vulnerability:** Lies in the zone of lowest oxygen tension (outer medullary core)
- **Metabolic demand:** High ATP consumption for active transport (50% of whole kidney oxygen consumption occurs in proximal tubule)
- **Microvascular anatomy:** Sparse peritubular capillary network; dependent on oxygen diffusion from descending vasa recta
- **Consequence:** When renal blood flow drops or oxygen demand surges, S3 segment becomes hypoxic first

**Clinical pearl:** S3 injury explains why **non-oliguric ATN is now more common** (70% of cases) — suggests incomplete tubular necrosis. Oliguric ATN reflects more severe, diffuse injury.

### Ischemia-Reperfusion Cascade

| Phase | Timeline | Mechanism | Pathology |
|----|----|----|----|
| **Ischemia** | During insult | ↓ ATP → loss of cell polarity, tight junctions leak | Necrosis, apoptosis |
| **Early reperfusion** | 0–6 hours | ROS generation, mitochondrial Ca2+ overload | Oxidative stress, more apoptosis |
| **Inflammatory phase** | 6 hours–3 days | Neutrophil infiltration, TNF-α, IL-1, IL-6 | Tubular obstruction by cellular debris |
| **Healing phase** | 3–7 days | Dedifferentiation → proliferation → redifferentiation | Restoration of architecture |

**Key mechanism:** ATP-dependent Na+/K+-ATPase on basolateral membrane loses function → intracellular Na+ rises → cell swelling → tight junctions disrupted → **backleak of glomerular filtrate** through paracellular pathway. ROS from NADPH oxidase and uncoupled mitochondrial respiration further damages lipid membranes and proteins.

### Sublethal Injury Concept

Not all tubular epithelial cells die; many suffer **sublethal injury**:

- Loss of microvilli and apical membrane specializations
- Cytoskeletal disruption (α-actin, β-actin filaments dissolve)
- Loss of epithelial-mesenchymal polarization
- Persistent mitochondrial dysfunction
- Delayed return to normal metabolic capacity

**Clinical implication:** Cells may survive but fail to filter effectively for days → prolonged AKI even as cellular death slows.

### Why Oliguria Develops: The “Three-Leak” Model

1.  **Backleak (paracellular):** Damaged tight junctions allow filtrate to leak back across tubular epithelium
2.  **Tubular obstruction:** Cellular debris, casts, and Tamm-Horsfall protein clogs collecting system → increased intratubular pressure
3.  **Tubuloglomerular feedback:** Rising distal NaCl delivery and increased intratubular pressure trigger juxtaglomerular apparatus reflex → afferent vasoconstriction → ↓ GFR

------------------------------------------------------------------------

## 2. Intrinsic Causes: Ischemic ATN

### Prolonged Hypotension and Shock States

**Surgical ATN:** Major surgery (especially cardiac, vascular, emergency) with intraoperative hypotension or aortic cross-clamping. - Incidence: 1–3% of major surgery; higher with pre-existing CKD - Risk factors: prolonged hypotension (\<60 mmHg mean arterial pressure), sepsis co-occurrence, nephrotoxin co-exposure (contrast, antibiotics) - Mechanism: S3 segment ischemia + reperfusion injury + inflammatory cascade

**Hemorrhagic shock:** Uncontrolled hemorrhage with delayed resuscitation. - ATN develops over hours if hypotension persists - Complicated by rhabdomyolysis (trauma) and transfusion reactions - Link to Rhabdomyolysis Management Guide

**Septic ATN:** Most prevalent ischemic ATN in ICU. - Multifactorial: splanchnic vasodilation → prerenal underfill + decreased GFR - Inflammatory cytokines (TNF-α, IL-1β) → tubular epithelial apoptosis - Mitochondrial dysfunction from endotoxin and reactive oxygen species - Microthrombi from DIC (if present) - Sepsis-associated AKI carries 50–70% mortality regardless of KRT modality

### Post-Cardiac Surgery AKI

- Incidence: 1–25% depending on definition (mild AKI vs. KRT-requiring)
- Mechanisms:
  - Cardiopulmonary bypass → non-pulsatile flow, microembolization
  - Aortic cross-clamp → direct renal artery occlusion
  - Hemodilution with bypass priming
  - Perioperative hypotension
  - Contrast exposure (coronary angiography pre-op)
- Outcomes: AKI doubles mortality; AKI requiring KRT carries 60% in-hospital mortality

**Prevention strategies:** - Minimize aortic cross-clamp time - Aggressive preoperative volume optimization - Avoid nephrotoxins perioperatively - Maintain MAP \>65 mmHg intraoperatively - Avoid hyperoxia (ROS generation)

### Contrast-Associated Acute Kidney Injury (Debated Mechanism)

**Ongoing controversy:** Is contrast-media AKI true ATN or hemodynamic/functional?

- **Classic hypothesis:** Direct osmotic/viscosity-mediated tubular cell toxicity, casting
- **Modern evidence:** Hemodynamic factors (volume depletion, reduced renal perfusion) may be primary driver
- **Risk factors:** CKD (eGFR \<30), diabetes, volume depletion, sepsis, use of high-osmolar contrast (now rare)
- **Prevention:** Pre- and post-hydration with isotonic saline, minimize contrast volume (contrast volume/eGFR ratio \<3.7)
- **Metformin consideration:** Withhold if eGFR \<30; resume 48 hours post-contrast if stable renal function
- **Incidence:** 2–7% in at-risk populations; most AKI is non-oliguric and recovers within 3–5 days

------------------------------------------------------------------------

## 3. Extrinsic Causes: Nephrotoxic ATN

### Pigment Nephropathy

#### Rhabdomyolysis-Induced ATN

**Pathophysiology:** - Myoglobin released from damaged muscle → freely filtered by glomerulus - In acidic urine, myoglobin precipitates → casts in collecting system - Myoglobin generates ROS → oxidative tubular injury - Myoglobin heme iron catalyzes Fenton reaction → hydroxyl radical formation - Myoglobin causes vasoconstriction (endothelin upregulation) - Associated hyperkalemia and hyperphosphatemia worsen prognosis

**Risk assessment:** CK elevation supports muscle injury, but CK alone does not predict an individual’s AKI risk or determine treatment. Assess volume depletion, initial creatinine, potassium, phosphate, calcium, bicarbonate, the cause, and comorbidity; a validated McMahon score can support risk assessment.

**Management:** Treat the muscle-injury cause, avoid additional nephrotoxins, and use isotonic crystalloid for indicated resuscitation with repeated perfusion, urine-output, and lung assessment. Do not keep increasing fluid for persistent anuria or congestion. Routine bicarbonate or mannitol is not recommended for AKI prevention. Check potassium/ECG and serial creatinine, CK, phosphate, and calcium. KRT is for refractory electrolyte or acid–base disturbance, pulmonary edema, or uremic complications; CK level or failure of urine output to respond to fluid alone is not an indication. [AAST consensus](https://tsaco.bmj.com/content/7/1/e000836).

#### Hemoglobinuria

- Massive intravascular hemolysis (transfusion reaction, PNH, MAHA, severe burns)
- Similar to myoglobin: free Hgb filtered, precipitates in casts, ROS generation
- Management: Identify and urgently treat the hemolysis cause, stop a causative transfusion when applicable, and support perfusion with fluid reassessment. Do not extrapolate routine urinary alkalinization from a theoretical pigment-precipitation mechanism; treat AKI complications on their clinical indications.
- Rare to cause AKI alone unless massive transfusion or severe hemolysis

### Antibiotic-Induced ATN

| Antibiotic | Mechanism | Segment | Timeline | Severity |
|----|----|----|----|----|
| **Aminoglycosides** | Lysosomal accumulation, mitochondrial dysfunction | S1-S2 proximal | 5–7 days (dose-dependent) | Usually non-oliguric; reversible |
| **Vancomycin** | Tubular epithelial toxicity, cast formation | Proximal + distal | 3–5 days (higher trough) | Non-oliguric; acute reversible |
| **Amphotericin B** | Oxidative injury, electrolyte wasting | Distal tubule, CD | Acute onset (first dose) | Oliguric possible; protracted |
| **Polymyxins** | Direct tubular toxicity | Distal/collecting duct | 3–7 days | Non-oliguric; reversible |
| **NSAIDs** | ↓ Renal perfusion + direct tubular effect | Variable | Acute | Prerenal + intrinsic |

**Aminoglycosides in depth:** - Uptake into proximal tubular cells via megalin-mediated endocytosis - Accumulate in lysosomes → phospholipidosis - Damage mitochondrial membrane and oxidative phosphorylation - **Non-oliguric ATN typical** — urine output maintained but creatinine rises - Recovery occurs but may be prolonged (weeks); rare cases of permanent CKD - **Risk mitigation:** Dosing interval optimization (extended-interval dosing, once-daily dosing), trough \<5 µg/mL for gentamicin, duration \<5–7 days - Links: antibiotic aki report, gentamicin aki timeline

**Vancomycin:** - Increasingly common as linezolid and daptomycin resistance emerges - Cast formation mechanism similar to contrast media - Trough \>20 µg/mL and prolonged exposure increase risk - AKI usually develops by day 3–5 of therapy - Link to vancomycin aki nephrotoxicity

### Chemotherapy-Associated ATN

#### Cisplatin Nephrotoxicity

- **Most nephrotoxic chemotherapy agent**
- Mechanism: S3 segment direct epithelial toxicity, oxidative stress, apoptosis
- Dose-dependent and cumulative (higher risk if cumulative dose \>300 mg/m²)
- Peak creatinine rise occurs 3–5 days post-infusion
- **Prevention:** Use the cisplatin regimen’s saline hydration and electrolyte protocol, including magnesium assessment/supplementation, with kidney-function and fluid-status monitoring. Do not impose a universal urine-output target above 250 mL/hour or routine forced diuresis. Mannitol may be used in selected high-dose regimens under local protocol; routine mannitol or furosemide has no established added benefit for every patient. [eviQ cisplatin prevention guidance](https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-treatment/184-prevention-and-management-of-cisplatin-induced).
- **Amifostine:** A selected cytoprotective option rather than routine cisplatin prophylaxis. Its US labeled kidney-protection indication is reduction of cumulative cisplatin renal toxicity in advanced ovarian cancer; its head-and-neck indication concerns radiation-related xerostomia. Selection requires oncology protocol review. [Ethyol prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a17563f2-d231-4385-bc94-0217be78b89d).
- Link to platinum nephrotoxicity review

#### Ifosfamide

- Proximal tubular dysfunction (Fanconi syndrome) with acute AKI possible
- Use the specific ifosfamide regimen’s hydration and uroprotection protocol, adapted to kidney function and fluid tolerance; hydration does not eliminate the risk of proximal tubular injury.
- Can cause chronic tubular dysfunction even if acute AKI averted

### Radiocontrast Agents

See **Contrast-Associated AKI** section above. Modern agents (iso-osmolar, low-osmolar) less nephrotoxic than older high-osmolar contrast media.

### Other Nephrotoxins

| Toxin | Mechanism | Presentation |
|----|----|----|
| **Ethylene glycol** | Metabolites (glycolic acid, oxalic acid) → acute ATN + hyperoxaluria | Acute AKI + metabolic acidosis, hypocalcemia |
| **Methanol** | Formic acid metabolite → ROS, mitochondrial damage | Similar to ethylene glycol |
| **Heavy metals** (mercury, lead, arsenic) | Direct tubular epithelial toxicity | Often chronic; acute ATN if massive exposure |
| **Calcineurin inhibitors** (tacrolimus, cyclosporine) | Dose-dependent vasoconstriction, tubular toxicity | Chronic \> acute; ATN rare unless overdose |
| **ACE-I/ARB in specific contexts** | Hemodynamic (not direct toxicity) in SIADH, sepsis, concurrent NSAIDs | Functional; not true ATN |

------------------------------------------------------------------------

## 4. Clinical Diagnosis of ATN

### Urinalysis and Urine Sediment (The Goldstandard for ATN Diagnosis)

**Hallmark finding: Muddy brown granular casts + renal tubular epithelial cells (RTECs)**

| Finding | Sensitivity | Specificity | Interpretation |
|----|----|----|----|
| **Muddy brown casts** | 50–60% | 95%+ | Pathognomonic for ATN (if present) |
| **RTECs or RTEC casts** | 70–80% | 85%+ | Suggests tubular damage |
| **Granular casts** | Variable | Moderate | Non-specific; can occur in CKD, prerenal AKI |
| **Hyaline casts** | 50%+ | Low | Non-specific; normal finding |
| **WBC casts** | \<5% | High | Suggests acute pyelonephritis (if present) |
| **RBC casts** | Rare | Very high | Suggests glomerulonephritis |

**Perazella-Coca urine sediment score** (2 points = ATN likely; ≥6 = ATN confirmed): - Each granular cast = 1 point - Each RTEC or RTEC cast = 2 points - Score ≥6 has 97% specificity for ATN

**Clinical note:** Absence of muddy brown casts does NOT exclude ATN; ~40% of ATN cases lack casts on urinalysis.

### Urine Chemistry: Limitations and Caveats

**Fractional Excretion of Sodium (FeNa)**

\$\$\text{FeNa} = \frac{U\_{\text{Na}} \times P\_{\text{Cr}}}{P\_{\text{Na}} \times U\_{\text{Cr}}} \times 100\\\$\$

- **Interpretation:** FeNa \<1% suggests prerenal; \>1% suggests intrinsic (ATN)
- **Problem:** ~10–20% of ATN cases have FeNa \<1% (false negatives)
- **Sepsis exception:** Most important — septic ATN often has FeNa \<1% due to hypotension triggering tubuloglomerular feedback
- **CKD exception:** Baseline FeNa often \>2% in CKD; less discriminatory
- **Myoglobinuria:** FeNa falsely low early in rhabdo (RTA mimics prerenal)
- **Diuretic use:** FeNa becomes unreliable within hours of diuretic dose
- **Volume expansion:** Aggressive fluid administration raises FeNa independently

**Fractional Excretion of Urea (FeUrea)**

\$\$\text{FeUrea} = \frac{U\_{\text{Urea}} \times P\_{\text{Cr}}}{P\_{\text{Urea}} \times U\_{\text{Cr}}} \times 100\\\$\$

- **Advantage over FeNa:** FeUrea \>35% more specific for ATN; less affected by diuretics, CKD
- **Interpretation:** FeUrea \>35% suggests ATN (even if FeNa \<1%)
- **Limitation:** Less widely used; urea lab often not routinely available as quickly as creatinine

**Bottom line:** FeNa and FeUrea are useful supportive tests but must be interpreted **alongside clinical context, urine sediment, and urinary biomarkers**. A FeNa \<1% does NOT rule out ATN in sepsis or early rhabdo.

### Urine Eosinophils: Limited Clinical Utility

- **Historical use:** Thought to indicate acute interstitial nephritis or drug allergy
- **Modern evidence:** Sensitivity ~60%, specificity ~85% at best; not reliable
- **Problems:** Can appear in prerenal AKI, ATN, glomerulonephritis
- **Bottom line:** Do NOT rely on urine eosinophils for AKI etiology diagnosis

### Biomarkers of Tubular Damage

| Biomarker | Location | Timeline | Advantage | Limitation |
|----|----|----|----|----|
| **NGAL** (Neutrophil Gelatinase-Associated Lipocalin) | Distal tubule | ↑ 2–4 hours post-insult | Early detection | Non-specific; rises in infection, inflammation |
| **KIM-1** (Kidney Injury Molecule-1) | S3 segment (apical) | ↑ 12–24 hours | Tubular specific | Research use; not clinical yet |
| **IL-18** (Interleukin-18) | Distal tubule, CD | ↑ 6–8 hours | Inflammatory marker | Non-specific |
| **IGFBP7/TIMP-2** | Proximal tubule | ↑ 4 hours (FDA-approved) | Early, sensitive | Cost; not universally available |

**Clinical reality:** - **NGAL:** Most developed; used in some ICUs for early AKI detection and AKI-RRT timing decisions - **Utility:** More sensitive for AKI development within 24–48 hours than creatinine, especially post-operative setting - **Limitation:** Not specific for ATN vs. other AKI etiologies; elevation seen in sepsis, hemolysis, transfusion - Link to AKI Biomarkers Comprehensive Review

------------------------------------------------------------------------

## 5. Management of ATN

### Supportive Care: The Foundation

#### Identifying and Removing Nephrotoxins

- **Aminoglycosides:** Switch to alternative antibiotic (carbapenems, fluoroquinolones, 3rd-gen cephalosporin depending on pathogen)
- **NSAIDs:** Discontinue immediately
- **ACE-I/ARB:** Hold during AKI phase (restart after recovery if creatinine stable)
- **Vancomycin:** If alternative available and eGFR dropping; if no alternative, extend dosing interval (Q12H → Q18–24H based on trough)
- **Diuretics:** Not preventive; avoid in early ATN (see below)
- **Contrast:** Defer elective procedures; if necessary, use lowest volume of iso-osmolar or low-osmolar agent with adequate hydration

#### Hemodynamic Optimization

- **Mean arterial pressure:** Target MAP \>65 mmHg (higher in sepsis until lactate clears)
- **Fluid resuscitation:** In non-oliguric ATN, replace measured output + insensible losses
  - **Challenge:** Over-resuscitation worsens outcomes in ARDS, cardiogenic shock
  - **Strategy:** Daily weight, CVP if available (target 8–12 mmHg in sepsis), ultrasound assessment of IVC
- **Vasopressors if needed:** Norepinephrine first-line (MAP target as above)
- **Avoid hypotension:** Every episode of SBP \<90 mmHg worsens AKI progression

#### Avoidance of Volume Overload

- **Paradox:** ATN requires adequate perfusion pressure BUT excessive hydration worsens outcomes
- **Oliguric ATN:** Restrict to replacement of measured losses (urine + insensible ~500 mL/day) once hemodynamically stable
- **Non-oliguric ATN:** Follow urine output more liberally but monitor for edema, pulmonary crackles, rising JVP
- **Weaning:** As urine output rises (sign of recovery), liberalize intake; as creatinine falls, weaning progresses

### Diuretics in ATN: Do NOT Improve Outcomes

**KDIGO 2012 Finding:** No mortality benefit to loop diuretics in AKI; no acceleration of recovery.

**Current role of diuretics:** - **NOT for prevention** or hastening recovery - **Utility:** Facilitating fluid management in anuric/oliguric patients on KRT - **Dosing if used:** High-dose boluses (furosemide 80–200 mg IV, or equivalent) followed by infusion; resistance common in AKI - **“Renal dose dopamine”:** NOT supported; do not use

**Why diuretics fail in ATN:** - Damaged tubular epithelium cannot reabsorb Na+ → loop diuretic has no additive effect - Backleak of filtrate negates diuretic effect - Reduced GFR limits drug delivery to tubular lumen

### Kidney Replacement Therapy: Indications and Timing

#### Indications (KDIGO-aligned)

| Indication | Urgency | Comment |
|----|----|----|
| **Hyperkalemia (K \>6.5 mEq/L)** | Emergent (if unresponsive to meds) | EKG changes + K \>6 → start KRT acutely |
| **Severe acidemia** | Urgent | pH \<7.15 from AKI with SOFA organ dysfunction |
| **Pulmonary edema** | Urgent | Refractory to diuretics; causing hypoxemia |
| **Uremia** | Urgent | BUN \>100–120 with encephalopathy, pericarditis |
| **Fluid overload** | Semi-urgent | \>20% above baseline weight with respiratory compromise |
| **Oligoanuria \>7 days** | Supportive | May need KRT even if BUN/K stable (nutritional support) |

#### Timing of KRT Initiation

**STARRT-AKI (2020, New England Journal of Medicine):** - Randomized 2,927 ICU patients with AKI Stage 2–3 to early (within 12 hours) vs. delayed KRT - **Finding:** NO mortality difference; delayed arm had ~70% eventually needed KRT - **Implication:** Earlier is not better; initiate based on metabolic indications, not stage alone

**AKIKI Trial (2016):** - Randomized 620 ICU patients (mostly sepsis) to early vs. delayed KRT - **Finding:** Delayed strategy (wait for urine output recovery or metabolic deterioration) reduced KRT need by 50%, no mortality difference - **Implication:** In septic AKI, delayed strategy safe if meticulously monitored

**Practical approach:** - **Initiate KRT when:** Hyperkalemia unresponsive, severe acidemia, pulmonary edema, BUN \>100 with uremia symptoms, fluid overload with respiratory compromise - **Defer if possible:** If creatinine rising but K \<6, pH \>7.20, urine output adequate, fluid status euvolemic - **Reassess daily:** As oliguria, hyperkalemia, or acidemia develops, initiate - **Modality:** CVVH (continuous) more common in ICU (hemodynamic stability, fluid management); IHD (intermittent) acceptable if stable and collaborative

#### Recovery Monitoring After KRT

- **Serial labs:** Creatinine daily (trajectory more important than absolute value), K, PO4, HCO3
- **Urine output trend:** Return of urine output (even modest amounts) often precedes creatinine fall
- **Weaning KRT:** Reduce frequency/duration when creatinine stable or falling; discontinue when able to maintain K \<6, PO4 \<6, HCO3 \>18

------------------------------------------------------------------------

## 6. Prognosis and Recovery

### Recovery Patterns by ATN Cause

| Cause | Oliguria Rate | Full Recovery | CKD at 1 Year | Mortality |
|----|----|----|----|----|
| **Ischemic ATN (post-surgical)** | 10–20% | 80–90% | 10–15% | 5–10% |
| **Ischemic ATN (septic)** | 25–35% | 60–70% | 20–30% | 40–70% |
| **Rhabdo-induced ATN** | 25–30% | 85%+ | 5–10% | 5% (if AKI managed) |
| **Aminoglycoside ATN** | \<5% (non-oliguric) | \>95% | \<5% | \<1% |
| **Cisplatin ATN** | 5–15% | 70–80% | 15–20% | 1–2% |
| **Contrast-induced ATN** | \<5% | \>95% | 5% | \<1% |

**Key prognostic factors:** - **Oliguria:** Oliguric ATN carries 2–3x higher mortality than non-oliguric - **Age:** \>70 years worsens prognosis - **Comorbidities:** CKD, diabetes, heart failure increase CKD progression risk - **Sepsis:** Dominates outcome; AKI is marker of severity, not independent killer - **Duration of AKI:** AKI lasting \>5–7 days more likely to progress to CKD

### Recovery Mechanisms

**Timeline:** - **Days 0–3:** Peak inflammation, ongoing apoptosis, no functional recovery - **Days 3–7:** Dedifferentiation of surviving tubular cells, initiation of proliferation (Ki-67+ cells appear) - **Days 7–14:** Re-differentiation, recovery of tight junctions, restoration of brush border - **Weeks 2–8:** Gradual restoration of tubular architecture; continued GFR improvement

**Cellular recovery:** ~70% of tubular cells survive even oliguric ATN; death is in minority. Recovery limited more by dysfunction of surviving cells than cell loss.

### AKI-to-CKD Transition: Maladaptive Repair

**Mechanisms linking ATN to chronic kidney disease:**

1.  **Incomplete repair:** Some tubular segments remain dedifferentiated or fibrotic
2.  **Epithelial-mesenchymal transition (EMT):** Some tubular epithelial cells transdifferentiate → myofibroblasts → excessive collagen deposition
3.  **Persistent inflammation:** Pro-inflammatory cytokines (TGF-β, TNF-α) persist weeks after AKI insult
4.  **Microvascular rarefaction:** Peritubular capillaries lost during AKI not fully restored
5.  **Fibrosis:** Myofibroblasts deposit collagen I and III → tubulointerstitial fibrosis
6.  **Oxidative stress:** Mitochondrial dysfunction persists → ROS generation → DNA damage accumulation

**Clinical implications:** - **15–25% of AKI survivors progress to CKD Stage 3–4** (especially if ATN severe or septic) - **Pre-existing CKD dramatically worsens AKI-CKD progression:** 30–40% progress if baseline eGFR \<30 - **Follow-up:** Serial creatinine at 3, 6, 12 months post-AKI; ~10% of baseline CKD-free patients develop CKD within 1 year - **Prevention:** Avoid repeat nephrotoxic exposures; control BP, diabetes, proteinuria post-recovery

### Chronic Kidney Disease Progression After ATN

**Risk factors for accelerated CKD:** - Advanced age at time of AKI - Female gender (possibly; conflicting literature) - Baseline CKD or reduced eGFR - Severe AKI requiring KRT - Sepsis-associated AKI - Multiple episodes of AKI - Persistent proteinuria post-recovery

**Surveillance strategy:** - Check creatinine at 1, 3, 6, 12 months post-discharge - Calculate eGFR trajectory (slope) - Assess for albuminuria at 3-month follow-up (proteinuria predicts CKD progression) - Consider nephrology referral if eGFR \<30 or rapid decline (\>5 mL/min/1.73m² per year)

------------------------------------------------------------------------

## 📚 References & Cross-Links

### Key Clinical Trials & Guidelines

- **STARRT-AKI Investigators; Bagshaw SM, Wald R, Adhikari NKJ, et al.** Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. *N Engl J Med.* 2020;383(3):240-251. [PMID: 32668114](https://pubmed.ncbi.nlm.nih.gov/32668114/). *— Accelerated vs standard KRT initiation in ICU AKI; no mortality benefit, more dialysis dependence with accelerated. Foundational evidence supporting watchful-waiting for non-emergent dialysis initiation.*
- **Gaudry S, Hajage D, Schortgen F, et al; AKIKI Study Group.** Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. *N Engl J Med.* 2016;375(2):122-133. [PMID: 27181456](https://pubmed.ncbi.nlm.nih.gov/27181456/). *— Early vs delayed RRT in ICU AKI; no difference in mortality, with reduced RRT exposure in delayed group. **Note — published in NEJM 375(2):122-133, NOT Lancet 388:175-187 as cited in the prior version of this file.***
- KDIGO Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl*. 2012;2:1–138. [Official guideline PDF (no standalone PubMed record)](https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf).
- **Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network (AKIN).** Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care.* 2007;11(2):R31. [PMID: 17331245](https://pubmed.ncbi.nlm.nih.gov/17331245/). *— AKIN classification and staging that informed KDIGO 2012; pre-KDIGO standard for ATN clinical research.*

### Related Topics in This Vault

- Rhabdomyolysis: Comprehensive Guide
- Antibiotic-Induced AKI
- Gentamicin Toxicity Timeline
- Vancomycin Nephrotoxicity
- Cisplatin and Ifosfamide Nephrotoxicity
- Comprehensive AKI Evaluation Strategy
- AKI Biomarkers: NGAL, KIM-1, IL-18
- ATN Management: Why Loop Diuretics Don’t Help
- ← Back to AKI Hub
- ← Back to Nephrology Hub

------------------------------------------------------------------------

## Teaching Summary

| Concept | Key Takeaway |
|----|----|
| **ATN Pathophysiology** | S3 segment damage → loss of cell polarity, backleak, tubular obstruction; non-oliguric now most common (70%) |
| **Ischemic ATN** | Sepsis most common ICU cause; hypotension drives S3 injury + reperfusion oxidative stress; post-op and post-shock ATN usually recovers |
| **Nephrotoxic ATN** | Review drug exposure and renal dosing. Cisplatin prevention uses an oncology hydration/electrolyte protocol; diuresis is not universal. Rhabdomyolysis requires cause treatment and volume-guided crystalloid, without routine urine alkalinization. |
| **Diagnosis** | Muddy brown casts + RTECs strongly support tubular injury in the appropriate clinical setting; FeNa \<1% does NOT exclude ATN (especially sepsis); urine biomarkers emerging |
| **Management** | Supportive care, hemodynamic optimization, avoid nephrotoxins; diuretics do NOT improve outcomes; KRT by metabolic need, not stage |
| **Recovery** | 70–90% recover baseline renal function; 15–25% progress to CKD; maladaptive repair (EMT, fibrosis) links ATN to chronic disease |

------------------------------------------------------------------------

*Document created 2026-02-28 for experienced clinicians. Update with new trial data and biomarker advances as available.*


---

[Website version](https://urinenephrology.org/mastery/aki-advanced/atn-comprehensive-intrinsic-extrinsic-review.html) · Markdown synchronized October 3, 2026.